Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.35−0.37 (-2.70%)
Close on Nov 20, 2026Market cap $1.90BP/E –Yield –
Trevi Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Trevi Therapeutics
Trevi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?